Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Komal Rastogi

Neurology West Valley City, UT Medical Doctor

NPI 1063774669 CMS profile 3061908

2965 W 3500 S, West Valley City, UT 84119

Open in the dashboard

General payments

$9,168

359 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Komal Rastogi of West Valley City, UT is reported in the CMS Open Payments database as having received $9,168 across 359 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,022 85
2024 General $1,213 62
2023 General $1,935 61
2022 General $815 30
2021 General $871 51
2020 General $537 37
2019 General $1,775 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Komal Rastogi
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Komal Rastogi were reported at $2,022. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Komal Rastogi Neurology median Middle half National median
2019 $1,775 $474 $118–$2,177 $163
2020 $537 $367 $82–$2,309 $114
2021 $871 $438 $104–$2,547 $132
2022 $815 $442 $103–$2,388 $149
2023 $1,935 $464 $119–$2,312 $160
2024 $1,213 $468 $119–$2,323 $164
2025 $2,022 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LivaNova USA, Inc. $1,627 29 payments
  2. Medtronic, Inc. $1,079 12 payments
  3. AbbVie, Inc. $694 37 payments
  4. Argenx US, Inc. $581 22 payments
  5. EMD Serono, Inc. $530 29 payments
  6. UCB, Inc. $462 19 payments
  7. TG Therapeutics, Inc. $276 10 payments
  8. ACADIA Pharmaceuticals Inc $266 13 payments
  9. Genzyme Corporation $228 10 payments
  10. Lundbeck LLC $221 13 payments
  11. Other $3,206 165 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,268 349 payments
  2. Travel and Lodging $1,569 7 payments
  3. Consulting Fee $213 1 payment
  4. Education $99 1 payment
  5. Debt forgiveness $19 1 payment
Products named General payments · program years 2019–2025
  1. VNS Therapy $1,493 22 payments
  2. PERCEPT PC BRAINSENSE $1,079 12 payments
  3. VYVGART Hytrulo $507 17 payments
  4. QULIPTA $493 27 payments
  5. BRIUMVI $276 10 payments
  6. ZEPOSIA $233 12 payments
  7. UBRELVY $229 13 payments
  8. NUPLAZID $182 8 payments
  9. VYEPTI $162 9 payments
  10. Rystiggo $158 5 payments
  11. Other $3,833 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,100

Median for Neurology: 833

Drug cost

$231,749

Median for Neurology: $202,670

Branded share of claims

23.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Avonex (4 Pack) Interferon Beta-1a Brand 13 $124,714
Ubrelvy Ubrogepant Brand 13 $15,448
Emgality Pen Galcanezumab-Gnlm Brand 13 $11,923
Aimovig Autoinjector Erenumab-Aooe Brand 13 $11,438
Memantine Hcl Generic 178 $6,955
Propranolol Hcl Er Propranolol Hcl Brand 79 $4,865
Carbidopa-Levodopa Carbidopa/Levodopa Brand 183 $4,372
Lacosamide Generic 30 $4,354
Primidone Generic 102 $3,991
Levetiracetam Generic 126 $3,732

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$86,811

Medicare's payments for the services billed

Medicare patients

433

Average age 74

Services billed

1,440

232 women, 201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 52%
Depression 34%
Ischemic heart disease 29%
Chronic kidney disease 29%
Diabetes 28%
Atrial fibrillation 21%
Alzheimer's or dementia 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYVGART Hytrulo
  • ARGENX US, INC. $149
$149 — —
BRIUMVI
  • TG Therapeutics, Inc. $103
$103 — —
VYEPTI
  • Lundbeck LLC $83
$83 — —
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $80
$80 — —
BOTOX
  • AbbVie, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

359 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record